The heavily indebted Canadian pharmaceutical company Valeant is understood to be close to making further progress in its programme of non-core disposals, as it seeks to reduce its near US$30bn…
Valeant eyes further disposal
The heavily indebted Canadian pharmaceutical company Valeant is understood to be close to making further progress in its programme of non-core disposals, as it seeks to reduce its near US$30bn…